SmallCap Ideas is an independent financial-media and research desk covering U.S. microcap and small-cap public companies. We profile the founders, products, balance sheets, and catalysts behind the names that fall below the institutional radar — written cleanly, sourced from filings, and built for investors who do their own work.
Each report is a stand-alone profile of a publicly traded company most institutional investors will never staff. Free to read on-site. Full Word-document version available for download after email subscribe.
A cleantech innovation engine where management argues a 48% stake plus 6% royalty in FDA-cleared Clyra Medical is, by itself, worth the parent's full market cap — and the other four operating units sit at zero.
Non-invasive fingerprint sweat testing growing 36% year-over-year while the parent operates under a June 15, 2026 Nasdaq compliance window. FDA 510(k) clearance for codeine is the binary 2026 catalyst.
A project-financed independent power producer with 23 battery storage projects across ERCOT, MISO, CAISO, and PJM — and $250 million in committed strategic capital. No project has reached commercial operation date yet.
Big-cap research is crowded. Our beat is everywhere else — the founders running real businesses inside the bid-ask spread, the issuers whose deck slides don't make it into a Bloomberg terminal, and the small-cap stories that move on a single 8-K.
We don't accept compensation from the issuers we cover, and we say so on every report. Our position on a company is the position visible in the filings.
Every claim ties back to an SEC filing, a primary press release, or a named third-party source. No anonymous insiders. No anonymous models.
We don't issue ratings, price targets, or recommendations. We profile companies, lay out the catalysts and the risks, and trust readers to do the rest.
For small-cap companies pursuing capital-markets visibility, the SmallCap Ideas platform is a credible, journalistic surface. For investors, it's a sourced research feed.
The companies we cover sit across the public small-cap landscape — emerging operators, post-IPO businesses, and platforms re-rating after a corporate event. We come at each sector the same way: filings first, narrative second, the catalyst calendar last.